Business
BioVersys Receives EMA Orphan Designation for the Combination of Alpibectir and Ethionamide for the Treatment of Tuberculosis
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Orphan designation is granted to drug candidates addressing life-threatening or chronically debilitating diseases affecting fewer than 5 in 10’000 EU residentsEMA orphan status provides key incentives, including reduced fees, research and clinical protocol support, and 10-year EU market exclusivity BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research
About this update from Bioversys Ag
[{"type":"image","alt":"BioVersys","displaySize":"","headline":null,"caption":"BioVersys","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_Zo6ExiGAEwq5bzAtMXIVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c1af1ca0425507c351838a72eb663c47","width":300,"height":65}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"BASEL, Switzerland, Aug. 27, 2025 (GLOBE NEWSWIRE) --","length":53,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Orphan designation is granted to drug candidates addressing life-threatening or chronically debilitating diseases affecting fewer than 5 in 10’000 EU residents","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"EMA orphan status provides key incentives, including reduced fees, research and clinical protocol support, and 10-year EU market exclusivity","length":145,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":314,"olType":false},{"type":"text","content":"BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today that the European Medicines Agency Committee for Orphan Medicinal Products (EMA COMP) has granted orphan designation for the combination of alpibectir and ethionamide (AlpE) for the treatment of tuberculosis (TB).","length":466,"tagName":"p"},{"type":"text","content":"Tuberculosis is one of the leading causes of death by infectious diseases globally, and many existing treatments are becoming less effective due to growing drug resistance. Alpibectir, a small molecule acting through a novel mode of action, represents a totally new concept of overcoming resistance by significantly potentiating the activity of an existing antibiotic, ethionamide (Eto). It is being developed for pulmonary and meningeal TB.","length":441,"tagName":"p"},{"type":"text","content":"EMA’s orphan designation follows a successful clinical Phase 2a proof of concept trial and FDA’s Orphan...